DMT As A Treatment For Stroke? This Company Is Closer To Launching Its Phase 2 Study
Portfolio Pulse from Vuk Zdinjak
Algernon NeuroScience, a subsidiary of Algernon Pharmaceuticals Inc., has completed a feasibility study and finalized its clinical trial design for a phase 2 DMT stroke study. The trial will study an intravenous sub-psychedelic dose of DMT in patients who have suffered an acute ischemic stroke. The decision to investigate DMT for stroke treatment was based on a 2020-published rat occlusion stroke study showing that DMT reduced infarct volume and led to almost full recovery of motor function. The company plans to conduct the study at multiple locations in Europe.

August 08, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Algernon Pharmaceuticals' stock may be impacted by the news of its subsidiary, Algernon NeuroScience, finalizing its clinical trial design for a phase 2 DMT stroke study.
The news of Algernon NeuroScience, a subsidiary of Algernon Pharmaceuticals, finalizing its clinical trial design for a phase 2 DMT stroke study could potentially impact the stock of Algernon Pharmaceuticals. However, the direction of the impact is uncertain as it depends on various factors including the market's perception of the potential success of the trial, the company's overall financial health, and the current market conditions.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100